Comparative Pharmacology
Head-to-head clinical analysis: EUTHROID 0 5 versus EUTHROID 2.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EUTHROID 0 5 versus EUTHROID 2.
EUTHROID-0.5 vs EUTHROID-2
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Euthyroid-0.5 is a combination of liothyronine (T3) and levothyroxine (T4). T4 is converted to the active T3 in peripheral tissues. T3 binds to thyroid hormone receptors (TRα and TRβ) in the nucleus, regulating gene transcription involved in metabolism, growth, and development.
EUTHROID-2 is a synthetic formulation of liothyronine (T3) and levothyroxine (T4) that replaces endogenous thyroid hormone. T4 is converted to the active T3 in peripheral tissues. T3 binds to thyroid hormone receptors in the cell nucleus, modulating gene transcription to increase metabolic rate, oxygen consumption, and protein, carbohydrate, and lipid metabolism.
Oral: 0.5 grains (30 mg) once daily, titrated to clinical response.
Oral, 1 tablet once daily. Each tablet contains levothyroxine 112 mcg and liothyronine 28.8 mcg.
None Documented
None Documented
Terminal elimination half-life is approximately 6-8 hours in adults with normal renal and hepatic function; clinically, steady-state is reached within 24-36 hours, and dosing interval adjustments may be needed in renal or hepatic impairment.
T4: 6-7 days (euthyroid); T3: approximately 1 day; clinical context: requires 6-8 weeks for steady state with T4 therapy.
Renal (approx. 20-40% as unchanged drug, primarily via glomerular filtration and tubular secretion); biliary/fecal (approx. 60-80% as metabolites and unchanged drug, with enterohepatic recirculation).
Renal: ~20-40% of T4 and T3 metabolites; fecal: ~40-60% as conjugated metabolites; minor biliary elimination.
Category C
Category C
Thyroid Hormone Replacement
Thyroid Hormone Replacement